Zacks Reiterates Outperform Rating, $9.50 PT on POZEN on PA-325/40 Product Data Presentations

In a report published Wednesday, Zacks reiterated its Outperform rating and $9.50 price target on POZEN

. Zacks noted, “The phase 3 clinical data on Pozen s PA-325/40 product has been presented now at three high-profile medical meetings, ACG in October 2012, AHA in November 2012, and AHA-Stroke in February 2013. We believe the results are highly encouraging with respect to reductions in gastric ulcers and discontinuations rates. We believe that PA-325/40 and lower-dose PA-81/40 has the potential to dramatically improve patient compliance and reduce adverse events associated with daily aspiring therapy, and thus it s a meaningful market opportunity for both Pozen and a potential commercialization partner.” POZEN closed on Tuesday at $6.15.